Abstract:Introduction Patients with transthyretin cardiac amyloidosis (ATTR-CA) and heart failure do not tolerate beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors due to side effects and the efficacy of these agents remains uncertain in this patient population. Sodium-glucose transporter 2 inhibitors (SGLT2i) have significantly improved clinical outcomes in patients with heart failure (irrespective of ejection fraction) with few side effects. However, there remains a lack of data on the safety and tolerability of SGLT2i in patients with ATTR-CA. Hypothesis This observational study describes the tolerability and safety of SGLT2i in patients with ATTR-CA and heart failure. Methods A single-center retrospective observation of consecutive adult patients with ATTR-CA initiated on SGLT2i from January 2020-March 2023. Results Our study involved 53 patients with ATTR CA (74% Wild-Type); mean age 81 years (SD ± 8), 77% white, 72% men, 32% had diabetes mellitus (DM), and 51% with at least stage 3 chronic kidney disease with a mean glomerular filtration rate of 58 mL/min/1.73m (SD ±18). The median left ventricular ejection fraction (LVEF) was 50% (IQR 36, 55). Of the 53 patients, 28% had an LVEF ≤ 40%, and 2% required inotrope, which was initiated at the same time as SGLT2i. In our study, 89% received empagliflozin and the rest dapagliflozin. The mean duration of treatment with SGLT2i was 19 months (SD ± 9). While on treatment with SGLT2i, 92% of patients were also on guideline-directed medical therapy (GDMT) with at least one agent. The most common GDMT used with SGLT2i was mineralocorticoid receptor antagonist (87%). Following initiation of SGLT2i, acute kidney injury (an increase in serum creatinine ≥ 0.3 mg/dL) developed in 3.8% (2) and urinary tract infection in 6% (3). New orthostatic hypotension was not noted in any patient following the initiation of SGLT2i. SGLT2i was discontinued in 6% (3) patients: following complicated UTI (1), discontinued by the patient (1), and transition to hospice (1). While on treatment with SGLT2i, 11% of the patients were admitted with at least one episode of heart failure exacerbation and no reported mortality for the duration of follow-up. Conclusions Our experience suggests that long-term use of SGLT2i is well-tolerated in patients with ATTR-CA, even with renal dysfunction, and irrespective of LVEF. The side effects were comparable to that reported in other heart failure populations. It also demonstrated that patients did not have worse outcomes while receiving SGLT2i, and hospitalizations for heart failure exacerbation were seen only in a few of the patients. The effects of SGLT2i on morbidity and mortality in ATTR-CA warrant further exploration.

Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety

Prognostic impact of SGLT2-inhibitor therapy on survival in patients with transthyretin amyloid cardiomyopathy

Analysis of a Prospective Registry Study

Inhibition Of Sodium-glucose Transport Protein As A Therapeutic Option In The Patients With Transthyretin Cardiac Amyloidosis

Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy

Short term effects of sodium-glucose cotransporter 2 inhibitors on lipid regulation in coronary artery disease patients undergoing Percutaneous Coronary Intervention: A Propensity-Matched Analysis

Safety and Tolerability of SGLT2 Inhibitors in Cardiac Amyloidosis—A Clinical Feasibility Study

SGLT2 inhibitors in patients with amyloidosis and heart failure: a worldwide retrospective cohort study

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence

Safety and Efficacy of Early SGLT2 Inhibitors Initiation in Diabetic Patients Following Acute Myocardial Infarction, a Retrospective Study

Cardiovascular Safety, Long‐Term Noncardiovascular Safety, and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Systemic Review and Meta‐Analysis with Trial Sequential Analysis

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials

Potential hematopoietic effects of SGLT2 inhibitors in patients with cardiac amyloidosis

Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis

Sodium-glucose cotransporter-2 inhibitors in acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials

Sodium-glucose co-transporter 2 inhibitors in left ventricular assist device and heart transplant recipients: a mini-review

Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care with or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure

Sodium–glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure

Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data